Excalibur Healthcare Services’ Licence And Development Agreement with AIM-listed Sensyne Health

Brown Rudnick LLP advised Excalibur Healthcare Services on the deal.

Excalibur Healthcare Services announced an exclusive licence and development agreement with AIM-listed Sensyne Health for the use of Excalibur’s tests in conjunction with Sensyne Health’s clinical AI software, ‘MagnifEye.’ The aim of the collaboration is to deliver the most accurate rapid lateral flow COVID-19 test in the world.

The initial focus of the collaboration will be for the use of the ‘MagnifEye’ technology for COVID-19 antigen testing, followed by its potential application in new lateral flow diagnostic tests for serology, cancer, and other disease conditions that Excalibur is currently developing.

Excalibur’s rapid SARS COV-2 antigen screening test was the first ever lateral flow antigen test to receive UK regulatory approval for use in mass screening for COVID-19 in asymptomatic, presymptomatic, and symptomatic populations. To date, the Excalibur COVID-19 antigen lateral flow diagnostic test has outperformed all other competing lateral flow tests with its speed, sensitivity, and reliability.

The Brown Rudnick team includes Neil Micklethwaite (Picture), managing partner of Brown Rudnick’s London office, Steven James, partner in the Intellectual Property Practice Group and Ruth Arkley, associate.

Involved fees earner: Ruth Arkley – Brown Rudnick; Steven James – Brown Rudnick; Neil Micklethwaite – Brown Rudnick;

Law Firms: Brown Rudnick;

Clients: Excalibur Healthcare Services;

Federica Tiefenthaler

Author: Federica Tiefenthaler